Biotech BD & Licensing Events

Tessera Defense and Homeland Security Inc., through its subsidiary Tessera Israel, entered into an Option Agreement with X S.E. Security and Defense Ltd. to potentially acquire a 51% stake in RT LTA Systems Ltd., a developer of tethered aerostat systems for surveillance. Tessera Israel paid $1 million for this 90-day option, which is creditable against the purchase price if exercised. The total purchase price for the 51% stake is capped at $13 million, with payments structured upon option exercise and based on RT's future financial performance.

Gossamer Bio, Inc. secured a private placement agreement to raise up to $250 million, with an initial $25.0 million closing. Additional funds of $125.0 million are contingent on FDA acceptance of the NDA for seralutinib in pulmonary arterial hypertension (PAH) by 2026, and a further $100.0 million from warrants upon FDA approval. Proceeds will support the clinical development and potential commercialization of seralutinib for PAH and PH-ILD.

Adagio Medical Holdings, Inc. has initiated a process to explore a full range of strategic alternatives to enhance shareholder value, which may include M&A. Concurrently, the company is reducing its workforce by 25 out of 43 full-time employees, effective September 23, 2026, anticipating approximately $1.3 million in cash expenditures for severance and related costs. The company also lowered the conversion price for its 13% Senior Secured Convertible Notes to facilitate potential conversions during this period.

Creative Medical Technology Holdings, Inc. acquired an additional 4,000,000 shares of BioDefense, Inc. common stock from Creative Acquisition Corp. for $200,000 in cash and 1,000,000 shares of its own common stock. This transaction increased Creative Medical Technology Holdings' ownership in BioDefense to 80% of outstanding shares. The Company's shares were issued in a private placement.

Ionis Pharmaceuticals and its partner Roche announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in proteinuria reduction compared to placebo. The safety profile of sefaxersen was consistent with previously reported data, with no new safety signals identified.